UZH Life Sciences Fund Invests in First Spin-off

CUTISS is a company with a vision: To use personalized skin grafts to heal people all over the world with skin defects, including burn victims. The UZH spin-off has developed a novel procedure whereby a postage-stamp-sized biopsy of healthy skin is harvested from the patient. This is then bioengineered to create a skin graft around 70 times larger in size in around a month. The skin produced in the lab and subsequently transplanted is elastic and grows with the patient. It is expected to result in less scarring than with conventional grafts and to provide a significantly better quality of life for patients. Taking development to market maturity. While the ground-breaking idea and its underlying innovative technology are in place and the first clinical safety trials have been successfully completed, the skin substitute - unique anywhere in the world - isn't yet ready for market.